Efficacy and Safety of Yangxin Shengmai Granules for the Treatment of Stable Angina Pectoris
Status:
Not yet recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blind, placebo-controlled, parallel clinical trial in
Chinese population with stable angina pectoris. The purpose is to determine the efficacy and
safety of Yangxin Shengmai Granules in the treatment of stable angina pectoris.
Phase:
Phase 4
Details
Lead Sponsor:
Guang'anmen Hospital of China Academy of Chinese Medical Sciences